Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Kyle LaHucik

Biotech Correspondent

Since Bernard Ravina’s medical training in neurology in the 1990s, there have been few new therapies that treat a movement disorder known as dystonia. …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation

Ex­clu­sive: Move­ment dis­or­der biotech Vi­ma steps on­to scene with $60M

Kyle LaHucik

Biotech Correspondent

Sign up to read this article for free.

Large phar­ma com­pa­nies spell out rea­sons why tar­iffs will harm US in­vest­ments

Supreme Court to keep mulling state PBM dis­pute as US urges jus­tices to de­cline case

Mer­ck, Dai­ichi Sankyo scrap FDA ap­pli­ca­tion for HER3 ADC af­ter sur­vival miss

DNA gi­ant Il­lu­mi­na spawned an ecosys­tem of com­peti­tors and cus­tomers

FDA re­jects Stealth's rare dis­ease drug, but of­fers po­ten­tial for ac­cel­er­at­ed ap­proval

From weeks to days: how Aizon In­tel­li­gent Agents trans­form phar­ma val­i­da­tion

Exclusive: Movement disorder biotech Vima steps onto scene with $60M

Large pharma companies spell out reasons why tariffs will harm US investments

Supreme Court to keep mulling state PBM dispute as US urges justices to decline case

Merck, Daiichi Sankyo scrap FDA application for HER3 ADC after survival miss

DNA giant Illumina spawned an ecosystem of competitors and customers

FDA rejects Stealth's rare disease drug, but offers potential for accelerated approval

From weeks to days: how Aizon Intelligent Agents transform pharma validation